Bacteriocin-Producing Probiotic Lactic Acid Bacteria against Hospital Strains of Staphylococcus aureus and Escherichia coli

It is now accepted that the human microbiome plays a key role in human health, and disturbances in the microbiome can cause or aggravate a range of diseases, from metabolic to immune disorders and mood disorders [1]. In addition, microbiota imbalance or dysbiosis may arise due to careless use of antibiotics in humans and animals, leading to the emergence of antibiotic-resistant bacteria that may compromise the effectiveness of antibiotics, so there is an urgent need to identify and develop new strategies to combat antibiotics resistance [2,3]. So far, probiotics are considered as perspective alternatives to antibiotics [4]. Probiotics are defined by the FAO/WHO as “Live microorganisms which when administered in adequate amounts confer a health benefit on the host” and they are successfully used for preservation of the microbial community [5].Moreover, bacteriocin-producing commensal microbes have the capacity to eliminate specific colonizing pathogens from various human body sites, and, as many bacteriocins have only narrow activity ranges they can be used for precision therapy and infections prevention [6]. Lactic acid bacteria, particularly lactobacilli, are the best known probiotics that modulate the immune system, and produce significant amounts of bioactive compounds, including bacteriocins, to eliminate pathogens and limit the clinical effects of antibiotic use [7, 8].